Vedolizumab

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication.

Journal: Scandinavian journal of gastroenterology

Published: January 16, 2026

Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's disease.

Journal: Zeitschrift fur Gastroenterologie

Published: January 12, 2026

Epstein-Barr virus colitis on a background of Crohn's disease.

Journal: BMJ case reports

Published: January 09, 2026

Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report.

Journal: Minerva gastroenterology

Published: January 09, 2026

Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment - A Case Report.

Journal: Zeitschrift fur Gastroenterologie

Published: January 08, 2026

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study.

Journal: Journal of Crohn's & colitis

Published: December 27, 2025

Research Progress on Exclusive Enteral Nutrition Combined with Biologics in the Treatment of Adult Crohn's Disease.

Journal: Journal of Crohn's & colitis

Published: December 26, 2025

Remission of Alopecia Areata Post-colectomy in a Patient with Crohn's Disease.

Journal: The Journal of clinical and aesthetic dermatology

Published: December 19, 2025

Effect of vedolizumab treatment on extraintestinal articular manifestations in patients with inflammatory bowel disease: meta-analysis.

Journal: Revista espanola de enfermedades digestivas

Published: December 18, 2025

Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.

Journal: Journal of Crohn's & colitis

Published: December 15, 2025

HLA-DQA105:01 and DQA105:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

Journal: Journal of Crohn's & colitis

Published: December 13, 2025

Whole genome sequencing confirms reactivation of Tuberculosis five years after initial infection despite adequate preventative therapy in a patient with profound immunosuppression.

Journal: QJM : monthly journal of the Association of Physicians

Published: December 10, 2025

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication.

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication.

Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's disease.

Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's disease.

Epstein-Barr virus colitis on a background of Crohn's disease.

Epstein-Barr virus colitis on a background of Crohn's disease.

Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report.

Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report.

Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment - A Case Report.

Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment - A Case Report.

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study.

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study.

Research Progress on Exclusive Enteral Nutrition Combined with Biologics in the Treatment of Adult Crohn's Disease.

Research Progress on Exclusive Enteral Nutrition Combined with Biologics in the Treatment of Adult Crohn's Disease.

Remission of Alopecia Areata Post-colectomy in a Patient with Crohn's Disease.

Remission of Alopecia Areata Post-colectomy in a Patient with Crohn's Disease.

Effect of vedolizumab treatment on extraintestinal articular manifestations in patients with inflammatory bowel disease: meta-analysis.

Effect of vedolizumab treatment on extraintestinal articular manifestations in patients with inflammatory bowel disease: meta-analysis.

Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.

Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.

HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

Whole genome sequencing confirms reactivation of Tuberculosis five years after initial infection despite adequate preventative therapy in a patient with profound immunosuppression.

Whole genome sequencing confirms reactivation of Tuberculosis five years after initial infection despite adequate preventative therapy in a patient with profound immunosuppression.

HLA-DQA105:01 and DQA105:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

HLA-DQA105:01 and DQA105:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.